As a leading global biotech organization, CSL is committed to protecting and improving human health. We condemn any unjustified acts of violence, including the war in Ukraine. We are deeply saddened by the devastating toll the invasion has inflicted on the Ukrainian people and we continue to diligently support our employees throughout Europe, their families and the communities impacted by this unjust act.
Aligned with Our Promise to protect human health, CSL is supporting multiple humanitarian relief efforts in the region. We are working with aid organizations, including the World Health Organization (WHO), the European Health Emergency preparedness and Response Authority (HERA), the EU Civil Protection Mechanism and the Red Cross to provide our life-saving medicines to those impacted by the invasion. We have also been coordinating our local relief efforts with international organizations, including Doctors Without Borders and UNICEF.
By providing our medicines through humanitarian, intergovernmental and EU-coordinated efforts, we will help refugees and those who remain in Ukraine access essential therapies.
In addition to providing our life-saving medicines, CSL has pledged to match monetary donations from our eligible employees around the world to support urgent relief efforts, including a program that enables eligible employees to donate plasma at CSL Plasma collection centers and then direct the payment to the Red Cross.
Together, our product and monetary contributions will continue to support relief efforts both within Ukraine and in neighboring countries.
While we continue to keep the Ukrainian people, and those in the surrounding regions, in our thoughts as we hope for a peaceful resolution, we also understand there are many people in Russia who rely on our life-saving therapies. CSL will continue to support those living with rare and serious diseases in Russia and supply products which are critical for patients. As the invasion persists, CSL will not conduct any promotional activities and will not start new clinical trials in Russia until further notice.